The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population.
OBJECTIVE
To compare men with prostate disease with those from the general population regarding polymorphisms in the androgen receptor gene and in the 5alpha-reductase II (SRD5A2) gene.


METHODS
The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with prostate cancer (CaP) (n=89), benign prostate hyperplasia (n=45) and healthy military conscripts (n=223).


RESULTS
The SRD5A2 high-activity allele variants A49T AT and V89L LL were more frequent in CaP-patients compared to general population, p=0.026 and p=0.05, respectively. CaP progression was, however, independent of SRD5A2 variants. In contrary, men with GGN<23 had a higher risk of dying from the disease than their counterparts with longer repeats.


CONCLUSIONS
Men with CaP were more often genetically predisposed to a higher enzymatic activity in the turn over from T to DHT compared to the general population. In our population, androgen receptor genotype affected CaP outcome.
Giwercman
Yvonne L
YL
Department of Urology, Malmö University Hospital, Lund University, Wallenberg Laboratory, entrance 46, SE - 205 02 Malmö, Sweden. yvonne.giwercman@kir.mas.lu.se
Abrahamsson
Per-Anders
PA
Giwercman
Aleksander
A
Gadaleanu
Virgil
V
Ahlgren
Göran
G
D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase / Q000097:blood / Q000235:genetics*; D000368:Aged; D000409:Alanine; D000483:Alleles; D001120:Arginine; D014408:Biomarkers, Tumor / Q000097:blood; D016022:Case-Control Studies; D013196:Dihydrotestosterone / Q000097:blood; D018450:Disease Progression; D005500:Follow-Up Studies; D020022:Genetic Predisposition to Disease; D005838:Genotype; D005973:Glutamine; D006801:Humans; D007930:Leucine; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008875:Middle Aged; D017354:Point Mutation; D011110:Polymorphism, Genetic; D011470:Prostatic Hyperplasia / Q000097:blood / Q000453:epidemiology / Q000235:genetics; D011471:Prostatic Neoplasms / Q000097:blood / Q000453:epidemiology / Q000235:genetics*; D011944:Receptors, Androgen / Q000097:blood / Q000235:genetics*; D012307:Risk Factors; D012738:Sex Hormone-Binding Globulin / Q000378:metabolism; D013548:Sweden / Q000453:epidemiology; D020079:Terminal Repeat Sequences; D013739:Testosterone / Q000097:blood; D013912:Threonine; D014633:Valine
D014408:Biomarkers, Tumor; D011944:Receptors, Androgen; D012738:Sex Hormone-Binding Globulin; D013196:Dihydrotestosterone; D005973:Glutamine; D013912:Threonine; D013739:Testosterone; D007986:Luteinizing Hormone; D001120:Arginine; D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase; D007930:Leucine; D014633:Valine; D000409:Alanine